Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy

See allHide authors and affiliations

Science Translational Medicine  12 Feb 2020:
Vol. 12, Issue 530, eaay8329
DOI: 10.1126/scitranslmed.aay8329

Article Information

vol. 12 no. 530

Print ISSN: 
Online ISSN: 
  • Received for publication July 23, 2019
  • Resubmitted November 12, 2019
  • Accepted for publication January 3, 2020
  • .

Author Information

  1. Jiang-Ping Song1,*,,
  2. Liang Chen1,*,
  3. Xiao Chen1,
  4. Jie Ren1,
  5. Ning-Ning Zhang1,
  6. Tiara Tirasawasdichai2,
  7. Zhen-Liang Hu1,
  8. Wei Hua1,
  9. Yi-Ran Hu1,
  10. Hui-Ru Tang3,
  11. Huei-Sheng Vincent Chen2, and
  12. Sheng-Shou Hu1,
  1. 1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital; National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100037, China.
  2. 2Krannert Institute of Cardiology (KIC), Indiana University, Indianapolis, IN 46202, USA.
  3. 3State Key Laboratory of Genetic Engineering, Zhongshan Hospital and School of Life Sciences, Human Phenome Institute, Metabonomics and Systems Biology Laboratory at Shanghai International Centre for Molecular Phenomics, Fudan University, Shanghai 200438, China.
  1. Corresponding author. Email: fuwaihss{at} (S.-S.H.); hsv_chen{at} (H.-S.V.C.); fwsongjiangping{at} (J.-P.S.)
  • * These authors contributed equally to this work.


Article usage

Article usage: February 2020 to February 2020

Feb 20204664655189

Stay Connected to Science Translational Medicine